If people spent less time going the early crow and then worrying...

If people spent less time going the early crow and then worrying about BoTs and MAnIpUlAtIon and comparisons to stocks that hold no relevance, and rather focused putting pressure on management to deliver some updates around the AuraIQ trials, might start to make more sense.

Signed roll-out for the distribution and commercialisation of AuraIQ product was first being mentioned over two years ago. Rather than the adhoc reference to trials every investor preso or quarterly, surely by now they have more specific feedback on where those trials are at, how they're faring and the like?

Markets are forward looking. Many are wise enough to look beyond the benefits of IMOD that make past, current and near-term financials look good. They want to see what financials in 18 months will look like. AuraIQ is the potential key to that, or another sizeable contract given it'll be a significant (near 100% margin) gap to plug. If headline figures show negative comparisons across a half when that contract finishes, it'll make it harder for management to sell the growth story